SCM
AVDL

Stonepine Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Stonepine Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-985,210
Closed -$10.3M – 28
2017
Q3 		$10.3M Buy
985,210
+237,347
+32% +$2.27M 6.1% 8
2017
Q2 		$8.25M Sell
747,863
-4,547
-0.6% -$45.7K 4.45% 9
2017
Q1 		$7.28M Buy
752,410
+426,323
+131% +$4.26M 4.1% 10
2016
Q4 		$3.39M Buy
+326,087
New +$3.58M 2.02% 16
2016
Q3 		– Sell
-128,005
Closed -$1.38M – 18
2016
Q2 		$1.38M Buy
+128,005
New +$1.36M 1.41% 16

Other funds holding AVDL

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Stonepine Capital Management's AVDL Position: Q4 2017 in Review

Stonepine Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q4 2017, closing a stake of 985,210 shares — an estimated $10.3M sold.

Stonepine Capital Management first reported a position in AVDL in Q2 2016 and held it in 5 quarters. The position peaked at $10.3M in Q3 2017. 83 funds tracked by Wall St. Rank hold AVDL as of Q4 2017.

  • Stonepine Capital Management reported no remaining Avadel Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Stonepine Capital Management sold 985,210 Avadel Pharmaceuticals shares in Q4 2017, an estimated $10.3M.
  • Stonepine Capital Management first reported a position in Avadel Pharmaceuticals in Q2 2016 and held it in 5 quarters.
  • Stonepine Capital Management's Avadel Pharmaceuticals position peaked at $10.3M in Q3 2017.
  • 83 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2017.

Based on Stonepine Capital Management's 13F filing for Q4 2017, filed 13 Feb 2018.